Navigation Links
European Patent Office Upholds Molecular Devices Planar Patch Clamp Patent
Date:5/18/2010

SUNNYVALE, Calif., May 18 /PRNewswire/ -- Molecular Devices today announced that European Patent Office (EPO) has upheld Molecular Devices foundational planar patch-clamp patent (EP No 1 040 349 B1).  The board will issue a written decision to this effect in the near future. The ruling will be the final determination of the EPO and cannot be appealed.  

(Logo: http://www.newscom.com/cgi-bin/prnh/20100406/SF82092LOGO)

"Molecular Devices is extremely pleased that the European Patent Office will uphold our planar patch-clamp patent," said Mark Verheyden, President of Molecular Devices, Inc. "This planar patch clamp patent is one of several that are of strategic importance to our automated electrophysiology business. The innovation that went into these patents enables the development of next generation automated electrophysiology platforms, such as the IonWorks Barracuda™ High-Speed Automated Patch Clamp System."

The ruling recognizes Molecular Devices novel application of using an electric field to position and seal cells for electrophysiological measurement on a planar substrate. This capability has revolutionized the way pharmaceutical and biotechnology companies screen new chemical entities against ion channel targets implicated in diseases such as, hypertension, cardiac arrhythmias, cystic fibrosis, immune disorders, and pathological pain.

The European Patent was originally filed with the EPO on 28 July 1998 and granted on 05 September 2001. Opposition of the patent was filed by a single company on the grounds that particular prior art deprived the patents of novelty or inventiveness. On 14 April 2010, the EPO found the patent to be novel and inventive with an amended set of method claims.    

About Molecular Devices: At Molecular Devices we have one focus—our customers. Whether a long-time user, recent adopter, or prospective customer, your needs fuel our actions. We hire creative, best-in-class people to design, manufacture, and commercialize analytical instruments, software, and assays as well as provide dedicated follow-on support. Understanding your laboratory workflow is our top priority, and we direct product development toward solving your unique issues. Our instruments offer a full spectrum of detection technologies and meet all throughput needs—from dedicated, single-readout devices to multi-readout systems. Our goal is to deliver highly relevant analytical products to detect biology, decode data, and drive discovery. With headquarters in Silicon Valley and offices around the globe, we support and enrich efforts of the international BioResearch, BioPharma, and BioTesting communities. Visit us today at www.MolecularDevices.com.  

Molecular Devices®, the Molecular Devices logo, IonWorks®, IonWorks Barracuda™, and all other trademarks are the property of Molecular Devices, Inc.


'/>"/>
SOURCE Molecular Devices, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
9. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/11/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading global ... solutions, today announced that it will release its second ... a conference call at 9:00am ET. The Company will ... and its strategy and outlook for the remainder of ... Raphael , Chief Executive Officer, and Zvi Ben-David ...
(Date:8/7/2017)... , Aug. 7, 2017 Insightin ... member acquisition, retention, and engagement, announced the selection ... Strategy and Product Development, effective as of February 2017. ... and technology implementation strategy for our clients. Wood ... experience in consulting and business analytics within the ...
Breaking Medicine Technology:
(Date:8/18/2017)... VA (PRWEB) , ... August 18, 2017 , ... ... asset protection services and financial consultations to communities throughout the greater DC region, ... K9 with the goal of rescuing local animals and training them to be ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Brian Gifford Agency, an Indiana-based firm ... in support of Campagna Academy in a charity drive to provide for at-risk children ... of Indiana,” Campagna Academy is a nonprofit organization that has offered critical programs to ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... practitioners specializing in bioidentical hormone replacement therapy and integrative medicine, has become a ... conditions of aging, such as menopause, andropause, thyroid disorder and adrenal insufficiencies. ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... tracking and monitoring solutions, announced today the launch of a redesigned corporate website, ... navigation and aesthetic, fully responsive design, and an enhanced search directory for businesses ...
(Date:8/18/2017)... ... ... “Beyond Our Imaginations: The Infinite God”: shows the importance of God in living ... of published author, Mark Lawrence, born in Michigan, the author has lived in various ... greater man of God is that I have to be more mindful of feminine ...
Breaking Medicine News(10 mins):